Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.
Nicholas J. Vogelzang
Consultant or Advisory Role - Algeta/Bayer
Svein Inge Helle
No relevant relationships to disclose
Dag Clement Johannessen
No relevant relationships to disclose
Joe M. O'Sullivan
No relevant relationships to disclose
Jose E. Garcia-Vargas
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
C. Gillies O'Bryan-Tear
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Minghua Shan
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Chris Parker
Consultant or Advisory Role - Algeta; Bayer; BN ImmunoTherapeutics
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi ; Takeda